Zheng Kangni, Heydari Bobak, Simon David K
Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA.
Arch Neurol. 2003 May;60(5):722-5. doi: 10.1001/archneur.60.5.722.
NURR1 plays a key role in mesencephalic dopaminergic neuron development and survival. A homozygous NURR1 polymorphism (a single base-pair insertion in intron 6) (NI6P) has been reported to be associated with Parkinson disease (PD).
To assess the association of the NI6P with PD and diffuse Lewy body disease.
Case-control study.
Movement disorders clinic and tissue provided by brain banks.
Patients with pathologically proven PD (n = 37) or diffuse Lewy body disease (n = 35), neuropathologically normal control subjects (n = 59), those clinically diagnosed as having PD (n = 66), and spousal controls (n = 29).
Determining the frequency of heterozygotes and homozygotes for the NI6P by DNA sequencing and restriction endonuclease analyses.
Overall, 41 (39.8%) of the 103 patients with PD were heterozygotes compared with 22 (25.0%) of the 88 controls (P =.03), with a relative risk (estimated from the odds ratio) for PD of 2.03 (95% confidence interval, 1.08-3.81) for heterozygotes vs wild type subjects. Heterozygotes were more frequent in the subgroup of patients with pathologically confirmed PD (18 [48.6%] of 37) vs controls (14 [23.7%] of 59) (P =.01), with a relative risk for PD of 2.84 (95% confidence interval, 1.17-6.88) for heterozygotes vs wild type subjects. In patients clinically diagnosed as having PD, heterozygotes were more frequent in early-onset cases (onset at < or =45 years) (10 [55.6%] of 18) compared with late-onset cases (onset at >45 years) (10 [23.8%] of 42) (P =.02) or spousal controls (8 [27.6%] of 29) (P =.06), with a relative risk for early-onset PD of 4.17 (95% confidence interval, 1.13-15.33) for heterozygotes vs subjects with 2 wild type alleles. The homozygous NI6P was not associated with PD, but was present in 6 (17.1%) of the 35 patients with diffuse Lewy body disease compared with 3 (5.1%) of the 59 controls (P =.06).
The common heterozygous NI6P is associated with an increased risk of PD. An association of borderline significance was found for the homozygous NI6P and diffuse Lewy body disease.
NURR1在中脑多巴胺能神经元的发育和存活中起关键作用。据报道,一种纯合的NURR1多态性(内含子6中的单碱基对插入)(NI6P)与帕金森病(PD)相关。
评估NI6P与PD及弥漫性路易体病的相关性。
病例对照研究。
运动障碍诊所及脑库提供的组织。
经病理证实的PD患者(n = 37)或弥漫性路易体病患者(n = 35)、神经病理学正常的对照者(n = 59)、临床诊断为PD的患者(n = 66)以及配偶对照者(n = 29)。
通过DNA测序和限制性内切酶分析确定NI6P杂合子和纯合子的频率。
总体而言,103例PD患者中有41例(39.8%)为杂合子,而88例对照者中有22例(25.0%)为杂合子(P = 0.03),杂合子与野生型受试者相比,PD的相对风险(根据比值比估算)为2.03(95%置信区间,1.08 - 3.81)。在病理确诊的PD患者亚组中,杂合子更为常见(37例中有18例[48.6%]),而对照者中为59例中有14例(23.7%)(P = 0.01),杂合子与野生型受试者相比,PD的相对风险为2.84(95%置信区间,1.17 - 6.88)。在临床诊断为PD的患者中,早发型病例(发病年龄≤45岁)的杂合子更为常见(18例中有10例[55.6%]),而晚发型病例(发病年龄>45岁)中为42例中有10例(23.8%)(P = 0.02)或配偶对照者中为29例中有8例(27.6%)(P = 0.06),杂合子与具有两个野生型等位基因的受试者相比,早发型PD的相对风险为4.17(95%置信区间,1.13 - 15.33)。纯合NI6P与PD无关,但在35例弥漫性路易体病患者中有6例(17.1%)存在,而59例对照者中有3例(5.1%)存在(P = 0.06)。
常见的杂合NI6P与PD风险增加相关。纯合NI6P与弥漫性路易体病存在边缘性显著关联。